| ○種別 (必須): | □ | 学術論文 (審査論文)
| [継承] |
| ○言語 (必須): | □ | 英語
| [継承] |
| ○招待 (推奨): |
| ○審査 (推奨): |
| ○カテゴリ (推奨): |
| ○共著種別 (推奨): |
| ○学究種別 (推奨): |
| ○組織 (推奨): | 1. | 京都大学
| [継承] |
| ○著者 (必須): | 1. | (英) Masunaga Shin-ichiro (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 2. | 永澤 秀子 (岐阜薬科大学/->個人[紺世 秀子])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 3. | 宇都 義浩 ([徳島大学.大学院社会産業理工学研究部.生物資源産業学域.応用生命系.応用生物資源学分野]/[徳島大学.生物資源産業学部.生物資源産業学科.応用生命講座])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 4. | 堀 均
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 5. | (英) Ohnishi K. (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 6. | (英) Takahashi A. (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 7. | (英) Ohnishi T. (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 8. | (英) Suzuki M. (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 9. | (英) Nagata K. (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 10. | (英) Kinashi Y. (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 11. | (英) Ono K. (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| ○題名 (必須): | □ | (英) Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells (日)
| [継承] |
| ○副題 (任意): |
| ○要約 (任意): | □ | (英) Human head and neck squamous cell carcinoma cells transfected with mutant TP53 (SAS/mp53) or with neo vector as a control (SAS/neo) were inoculated subcutaneously into both the hind legs of Balb/cA nude mice. Mice bearing the tumors received 5-bromo-2'-deoxyuridine (BrdU) continuously to label all proliferating (P) cells in the tumors. The mice then received a hypoxic cytotoxin, tirapazamine (TPZ) or TX-402, with or without a vascular targeting agent (VTA), ZD6126. Another group of mice given ZD6126 received a series of test doses of gamma-rays while alive or after tumor clamping to obtain hypoxic fractions (HFs) in the tumors. After each treatment, the tumor cells were isolated and incubated with a cytokinesis blocker (cytochalasin-B), and the micronucleus (MN) frequency in cells without BrdU labeling [quiescent (Q) cells] was determined using immunofluorescence staining for BrdU. The MN frequency in total (P+Q) tumor cells was determined from the tumors that were not pretreated with BrdU. Both hypoxic cytotoxins showed significantly greater toxicity toward SAS/mp53 and Q than SAS/neo and total tumor cells, respectively. The sensitivity to TX-402 was significantly higher than that to TPZ in both total and Q tumor cells of both tumors. The significant enhancive effect by ZD6126 combined with each hypoxic cytotoxin was similar irrespective of p53 status, and slightly greater for total than Q cells probably because of a more marked increase in the size of the HFs in total than Q cells on the use of ZD6126 in both tumors, resulting in a reduction of the difference in the sensitivity to the hypoxic cytotoxin between total and Q cells. In the treatment of conventional cancer therapy-resistant Q tumor cells or p53-mutated tumor cells, the use of hypoxic cytotoxin was very promising either alone or when VTA was co-administered. TX-402 might be more promising than TPZ, although further study of the toxicity to normal tissue is needed. (日)
| [継承] |
| ○キーワード (推奨): | 1. | (英) Animals (日) (読)
| [継承] |
| 2. | (英) Antineoplastic Combined Chemotherapy Protocols (日) (読)
| [継承] |
| 3. | (英) Carcinoma, Squamous Cell (日) (読)
| [継承] |
| 4. | (英) Cell Hypoxia (日) (読)
| [継承] |
| 5. | (英) Cell Line, Tumor (日) (読)
| [継承] |
| 6. | (英) Cell Proliferation (日) (読)
| [継承] |
| 7. | (英) Cell Survival (日) (読)
| [継承] |
| 8. | (英) Combined Modality Therapy (日) (読)
| [継承] |
| 9. | (英) Cyclic N-Oxides (日) (読)
| [継承] |
| 10. | (英) Gamma Rays (日) (読)
| [継承] |
| 11. | (英) Head and Neck Neoplasms (日) (読)
| [継承] |
| 12. | (英) Humans (日) (読)
| [継承] |
| 13. | (英) Mice (日) (読)
| [継承] |
| 14. | (英) Mice, Inbred BALB C (日) (読)
| [継承] |
| 15. | (英) Mice, Nude (日) (読)
| [継承] |
| 16. | (英) Micronucleus Tests (日) (読)
| [継承] |
| 17. | (英) Mutation (日) (読)
| [継承] |
| 18. | (英) Organophosphorus Compounds (日) (読)
| [継承] |
| 19. | (英) Quinoxalines (日) (読)
| [継承] |
| 20. | (英) Radiotherapy (日) (読)
| [継承] |
| 21. | (英) Triazines (日) (読)
| [継承] |
| 22. | (英) Tumor Suppressor Protein p53 (日) (読)
| [継承] |
| 23. | (英) Xenograft Model Antitumor Assays (日) (読)
| [継承] |
| ○発行所 (推奨): |
| ○誌名 (必須): | □ | Oncology Reports (Ethnikon Hidryma Ereunōn (Greece))
(pISSN: 1021-335X, eISSN: 1791-2431)
| ○ISSN (任意): | □ | 1021-335X
ISSN: 1021-335X
(pISSN: 1021-335X, eISSN: 1791-2431) Title: Oncology reportsTitle(ISO): Oncol. Rep.Publisher: Spandidos Publications (NLM Catalog)
(Scopus)
(CrossRef)
(Scopus information is found. [need login]) | [継承] |
| [継承] |
| ○巻 (必須): | □ | 14
| [継承] |
| ○号 (必須): | □ | 2
| [継承] |
| ○頁 (必須): | □ | 394 400
| [継承] |
| ○都市 (任意): |
| ○年月日 (必須): | □ | 西暦 2005年 7月 初日 (平成 17年 7月 初日)
| [継承] |
| ○URL (任意): |
| ○DOI (任意): |
| ○PMID (任意): | □ | 16012721 (→Scopusで検索)
| [継承] |
| ○NAID (任意): |
| ○WOS (任意): | □ | 000230539600016
| [継承] |
| ○Scopus (任意): |
| ○評価値 (任意): |
| ○被引用数 (任意): |
| ○指導教員 (推奨): |
| ○備考 (任意): | 1. | (英) Article.Affiliation: Radiation Oncology Research Laboratory, Research Reactor Institute, Kyoto University, 2-1010, Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan. smasuna@rri.kyoto-u.ac.jp (日)
| [継承] |
| 2. | (英) Article.PublicationTypeList.PublicationType: Comparative Study (日)
| [継承] |
| 3. | (英) Article.PublicationTypeList.PublicationType: Journal Article (日)
| [継承] |
| 4. | (英) Article.PublicationTypeList.PublicationType: Research Support, Non-U.S. Gov't (日)
| [継承] |